Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin C  COVID-19 treatment studies for Vitamin C  C19 studies: Vitamin C  Vitamin C   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 42% Improvement Relative Risk Ventilation 41% Hospitalization 61% c19vitaminc.com Sinnberg et al. Vitamin C for COVID-19 Sufficiency Favors vitamin C Favors control
Sinnberg, 74 patient vitamin C sufficiency study: 42% lower mortality [p=0.38], 41% lower ventilation [p=0.17], and 61% lower hospitalization [p=0.05] https://c19p.org/sinnberg
copied to clipboard
Vitamin C Deficiency in Blood Samples of COVID-19 Patients
Sinnberg et al., Antioxidants, doi:10.3390/antiox11081580
15 Aug 2022    Source   PDF   Share   Tweet
Analysis of 74 COVID-19 patients and 8 controls in Germany, showing low vitamin C levels associated with mortality. There was no significant difference for vitamin A, D, or E levels. Very few group details are provided, for example the age of patients in the control group and each severity group is not provided.
risk of death, 41.9% lower, HR 0.58, p = 0.38, treatment 0 of 15 (0.0%), control 9 of 59 (15.3%), NNT 6.6, adjusted per study, inverted to make RR<1 favor treatment, survival analysis.
risk of mechanical ventilation, 40.9% lower, HR 0.59, p = 0.17, treatment 15, control 59, adjusted per study, ventilation time survival analysis.
risk of hospitalization, 60.7% lower, HR 0.39, p = 0.0498, treatment 15, control 59, adjusted per study, hospitalization time survival analysis.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sinnberg et al., 15 Aug 2022, retrospective, Germany, peer-reviewed, 15 authors, study period February 2020 - November 2020.
Contact: luigi.marongiu@uni-tuebingen.de (corresponding author), sascha.venturelli@uni-hohenheim.de.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin CAll
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit